Tag Archives: bit.bio’s opti-ox™

BlueRock Therapeutics and bit.bio Collaborate on iPSC-Derived T Cell Therapies for Autoimmune Disorders

(IN BRIEF) BlueRock Therapeutics and bit.bio have announced a collaboration and option agreement to discover and manufacture iPSC-derived regulatory T cells (Tregs) for therapeutic use. Tregs are crucial for immune system balance and controlling excessive immune reactions, making them potential … Read the full press release